Duke Cancer Institute’s breast oncology program offers advanced diagnostics, genetic and prevention counseling, as well as the full scope of treatments for early, advanced-stage, metastatic, and rare forms of breast cancer.
Visit DukeHealth.org for more information about breast cancer treatment.
The Duke breast oncology program provides highly specialized care for all types of breast cancer, from the most common type, ductal carcinoma, to more aggressive and rare types of breast cancer such as inflammatory breast cancer, and phyllodes tumors.
Many of our specialists are nationally recognized for their breast cancer expertise. The team’s groundbreaking research has resulted in the FDA approval of breast cancer treatments. Most recently, research that originated in a Duke Cancer Institute laboratory contributed to the FDA approval of elacestrant, the first new endocrine therapy for breast cancer in more than 20 years. It is the only drug designed to target mutations in estrogen receptor 1 (ESR1).
The new therapy, a selective estrogen receptor down regulator (SERD), was approved by the FDA in January 2023 for the treatment of estrogen receptor-positive/HER2-negative ESR1-mutated advanced or metastatic breast cancer in patients who were not treated successfully with at least one previous endocrine therapy.
Areas of Expertise
Duke breast medical, surgical, and radiation oncologists specialize in treating benign and malignant breast disease as well as high-risk conditions. Specifically, our areas of expertise include:
Advanced Screening, Prevention, and Treatment
As a team, we are experts in assessing breast cancer risk, hereditary breast cancer, and the use of high-risk screening. Our board-certified breast imaging specialists are trained in the early detection of breast cancer and the identification of abnormal breast imaging.
Screening starts with mammography, followed by breast ultrasounds and breast MRIs. We use fast breast MRI and contrast-enhanced breast MRI to capture clearer images and locate small lesions that can be missed on mammography. This is especially important in younger women with dense breast tissue and in women with breast implants.
Our breast cancer team partners with Duke researchers who have basic, translational, and clinical research interests in breast cancer. Our clinical trials study new ways to diagnose, prevent and treat breast cancer, and improve survivors’ quality of life. The trials give eligible breast cancer patients access to new therapies before they are approved.
Areas of Focus
Our physicians are investigating new ways to approach breast tumors, how exercise impacts treatment and survival, and how to improve the quality of our patients’ lives. Our trials test new vaccines to treat different types of breast cancer, including early-stage breast cancer and HER2-positive breast cancer.
These subprograms focus on translating basic science discoveries to impact the early detection and treatment of breast cancer:
Early detection strategies for breast cancer
Epigenetic therapy in breast cancer treatment
Basic breast cancer biology and novel therapeutic targeting
Disparities in breast cancer care
Duke Consortium for Inflammatory Breast Cancer
The Duke Consortium for Inflammatory Breast Cancer brings together investigators and clinicians to better understand, prevent, and treat inflammatory breast cancer. The Consortium works with advocates and community health providers as well as the World IBC Consortium investigators across many institutions.
Recent discoveries in genetics and genomics hold great promise. Our multi-disciplinary research team hopes to translate these discoveries into the next generation of targeted therapeutic approaches for the prevention and treatment of breast cancer.
A new series from Medscape "Better with Age: Improving Breast Cancer Care in Older Adults" featuring Duke and UNC clinicians, launched in March and continues through this fall. So far three of four video episodes are available to watch. They are as follows: Episode 1: The Difference Age Makes || Episode 2: Front and Center || Episode 3: Tailoring Treatment || Episode 4: Upgrading the Assessment (coming soon). Series screenshots include: Gretchen Kimmick, MD (top right); Rebeca Shelby, PhD (bottom right); Gretchen Kimmick, MD, studies a breast image (bottom left, left); physical therapist Lisa Massa, CLT, PT, WCS (bottom left, right)
Nearly 20% of women diagnosed with breast cancer are over 75. The number is growing. Older breast cancer patients commonly pose clinical challenges, such as frailty, comorbidities, and limited functional independence. In a new four-part Medscape video podcast series, DCI breast oncologist Gretchen Kimmick, MD, DCI psychologist Rebecca Shelby, PhD, and physical therapist Lisa Massa, CLT, PT, WCS, offer some strategies for optimal treatment of geriatric cancer patients. WATCH
On September 13, the White House Cancer Moonshot program announced its support for and commitment to several new projects to "end cancer as we know it," including a new initiative led by TOUCH, the Black Breast Cancer Alliance, to bolster Black women’s breast cancer clinical trial participation by 2025 — with the goal of reaching 350,000 Black women and motivating 25,000 into trial portals.
The White House also announced a connected program, TOUCH Care, the first program to provide a nurse navigator service to assist Black breast cancer patients in clinical trials. This will include developing culturally-agile recruiting materials, training trial staff, and coaching patients. TOUCH Care is being led by TOUCH co-founder and Duke Cancer Institute patient navigator and patient navigation manager Valarie Worthy, MSN, RN, and piloted with Genentech, which will add five breast cancer clinical trials annually.
Worthy, a two-decade-plus breast cancer survivor, has been a nurse for more than 38 years and worked at Duke for the past 19 years. Her hometown is Ahoskie, in northeastern North Carolina.
VIEW White House Fact Sheet
VIEW Genentech Press Release
POWER TEAM: Nadine Barrett, PhD, MS, MA; Tomi Akinyemiju, PhD, MS; Angelo Moore, PhD, MSN, RN
In continuing efforts to expand Duke Cancer Institute’s community outreach and engagement matrix of research, programs, and strategic partnerships to reduce the cancer burden and close the cancer disparities gap in its catchment area, DCI senior leadership is excited to welcome a new leader to the COE team.
On Feb. 1 this year, cancer epidemiologist Tomi Akinyemiju, PhD, MS, was named DCI’s new associate director of Community Outreach and Engagement. (how to say her name)
“She's a rising star in the world of cancer epidemiology and cancer disparities,” said deputy director of DCI Steven Patierno, PhD, who provides senior oversight to DCI’s community outreach and engagement efforts and helped recruit her to Duke two years ago. “She’s still in the early stages of her career but is already funded with an R01 from the National Cancer Institute. She’s also doing extraordinary work on breast cancer disparities in women of African ancestry. It’s very exciting research at the intersection of social determinants of health and the biology of cancer.”
Akinyemiju joined Duke and DCI in Feb. 2019 as an associate research professor in the Department of Global Health and as an associate professor in the Department of Population Health Sciences where she also serves as vice-chair for Diversity, Equity, and Inclusion. She has a secondary appointment in the Department of Obstetrics & Gynecology.
“Duke is a very well-known brand, a well-known institution with really cutting-edge smart people doing outstanding research,” she said. “I was really excited to come here, to be in North Carolina and be in an environment that values innovation, excellence and collaboration.” Previously, Akinyemiju was Assistant Dean for Inclusive Excellence and an associate professor of epidemiology with the Markey Cancer Center at the University of Kentucky.
Akinyemiju’s current research to improve public health is focused on studying the social and biological mechanisms driving disparities in cancer risk, tumor aggressiveness and survival.
“Access to care is a very consistent theme in my work,” she said. “In Kentucky, there is the Appalachian region, with underserved and low-income white populations. Similarly, in North Carolina, we have pockets where there is a lack of access to care as well as low-income underserved minority populations.”
Akinyemiju is midway through a five-year $2 million NIH/National Cancer Institute-funded R01 study to assess the relative importance of race-specific barriers to healthcare access in Black and
White ovarian cancer patients across nine states in the US, including Kentucky and North Carolina, and evaluating the impact of healthcare access on quality of cancer treatment, quality of life, and ovarian cancer survival. She expects that these new insights will help identify and prioritize ways to reduce disparities and improve care for these patients.
Akinyemiju was born in Michigan, but grew up in Nigeria. She came back to her birthplace in 2004 for her undergraduate, graduate, and post-graduate education, but her latest research project, also NIH/NCI-funded, brings her back to where she grew up.
Nigeria, which is seeing a rapid increase in breast cancer cases in addition to other non-communicable diseases, including obesity-related diabetes, has the highest breast cancer mortality rates on the African continent. Triple negative breast cancer, an aggressive, fast-growing hard-to-treat subtype with a poor prognosis, is the most prevalent breast cancer sub-type at nearly 45% of breast cancer cases.
Akinyemiju is exploring how rising rates of metabolic dysregulation brought on by changing lifestyle and dietary patterns may impact breast cancer risk in Nigeria. To do this she’s collecting biospecimens in women with and without the triple negative breast cancer subtype in order to study the biological mechanisms of different subtypes that could predispose one person over another to be at higher-risk. She also plans to extend this study to the U.S. to examine biological data in African American breast cancer cases where the triple negative breast cancer prevalence is 20%. One outcome could be the discovery of an epigenetic (heritable DNA changes) link to triple negative breast cancer in those of West African heritage, including Americans with enslaved ancestors of West African descent.
“In this study, we are interlinking genomic data with social determinants of health,” Akinyemiju explained. “We need more research to figure out what the risk factors and biological mechanisms are and what we can target to treat. We’re having to build this data from scratch, but once we build it, the implications for important scientific discoveries are endless.”
UPDATE JAN. 27, 2023:Today the FDA approved the targeted therapeutic Elacestrant to treat certain postmenopausal women or adult men with advanced or metastatic ER-positive, HER2-negative, ESR1-mutated breast cancer after one or more lines of endocrine therapy.LEARN MORE
More than 1.5 million women in theU.S. are currently on endocrine therapies (hormone therapies) for breast cancer — either as monotherapiesor in combination with other drugs.
These drugs and drug combinationshave been found to work well, in somecases for many years until they don’t. Recently it has been demonstrated that mutations can develop in genes within breast cancer cellsthat render even the best endocrine therapies ineffective. While moreand more women are living with stage 4 breast cancer (upwardof 150,000), 42,000 die of metastatic breast cancer each year.Metastasis, cancer that has spread to distant organs, is the majorcause of breast cancer death.
The majority of breast tumors (~75%) have receptors for estrogens within cancer cells and such cancers are classified as ER+. When estrogens bind to these receptors, they can drive processes responsible for tumor growth and metastasis.
One type of anti-estrogen hormone therapy (endocrine therapy) — aselectiveestrogenreceptormodulator (SERM) — works by binding to the estrogen receptors present in cancer cells and in the body’s immune cells. This stops the estrogens from binding and driving cancer cell growth. Another type of endocrine therapy, aromatase inhibitors, suppresses estrogen synthesis.
SERMs (such as tamoxifen), aromatase inhibitors (such as anastrozole, letrozole, or exemestane), andcyclin-dependentkinase 4/6 inhibitors (therapies that target the CDK4 and CDK6 enzymes important to cell division, such as abemaciclib, ribociclib, and palbociclib) — taken alone or in combinations thereof — are currently used as first- and second-line treatments for ER+ breast cancer. (CDK 4/6 inhibitors are targeted therapies, not endocrine therapies)
Unfortunately, the majority of patients with metastaticER+breast cancer will eventually develop resistance to these drugs.
When this happens, oncologists may try a different type of endocrine therapy, aselectiveestrogenreceptordownregulator (SERD),which, like a SERM works bytargeting the estrogen receptor in cancer cells and the body’s immune cells, but instead ofblocking estrogen bybindingto theestrogen receptor like a SERM, itblocks estrogen bydegradingthe estrogen receptor.
The only drug of this class (SERD) approved for clinical use in ER+ breast cancer is fulvestrant (first FDA-approved in 2002), which has been shown to have only modest efficacy.Additionally,as an injectable drug, the administration of fulvestrant can be very uncomfortable for patients.
part of a Special Report by Duke Cancer Institute & the Department of Pathology, Duke University School of Medicine — as featured in the 2021-22 Department of Pathology Annual Report (pdf)
Oncologists today have a wider range of anti-cancer drugs to reach for, many of which target the molecular alterations believed to contribute to the cancer’s development.
Comprehensive genomic profiling, also known as next-generation sequencing (NGS), is used to identify these molecular alterations. Duke Cancer Institute (DCI) oncologists partner with Duke University Health System (DUHS) Clinical Labs and private diagnostics companies to test patients at diagnosis and/or after the cancer grows or spreads.
While it can vary across cancer types, increasingly, targeted therapies that can save patients from needing toxic chemotherapy are becoming available at multiple points in a patient’s cancer treatment, from first line standard of care to subsequent treatment after progression on conventional therapies.
Test results are entered into a Molecular Registry of Tumors known as Frameshift MRT. This centralized informatics tool — designed, built, and coded at Duke byMichael Datto, MD, PhD, (currently the medical director of DUHS Clinical Labs and vice chair for Clinical Pathology) and Christopher Hubbard (DUHS clinical informatics architect) — helps oncologists identify if anything in their patient’s mutational profile, even extremely rare targets, can be treated with any existing targeted therapies or immunotherapies.
Duke Cancer Institute has been offering its patients NGS testing since 2014. Developing Frameshift MRT three years later to organize and optimize the growing volume and complexity of data, and the subsequent formation, in early 2018, of a weekly multidisciplinary Molecular Tumor Board to review complex patient cases was a perfectly timed great leap forward.
The Precision Cancer Medicine Initiative — launched in 2017 by DCI, the BioRepository & Precision Pathology Center (BRPC), and the Clinical Labs — was the critical push behind it.
“It had become increasingly clear that the needs of sophisticated cancer researchers were changing across all cancer types; moving away from generic, archived, cancer-tissue samples, to fresh samples, to samples with a specific molecular abnormality,” explains Shannon McCall, MD, director of the BRPC, a DCI and Duke University School of Medicine Shared Resource housed in the Department of Pathology. “This coincided with clinical advances. Providers, including at DCI, were utilizing these broad molecular profiling assays to direct the care of cancer patients. There was a need to harness all this molecular profiling data to support both cancer research and treatment. I was totally on fire to get this started. We have so many big thinkers at Duke who said, ‘Let’s think about data and what’s possible.’”
In mid-2018, Executive Director of DCI Michael Kastan, MD, PhD, a noted cancer biologist, and Chair of the Department of Pathology Jiaoti Huang, MD, PhD, a prostate cancer researcher, signed a memorandum of understanding to co-fund the staffing necessary to further support the Molecular Tumor Board — co-directed by oncologists John Strickler, MD (for solid tumor cancers), and Matthew McKinney, MD (for blood cancers) — and to manage the Frameshift MRT database. This included hiring a bioinformatician/ data analyst (Jonathan Bell, PhD) and a savvy genetics scientist (Michelle Green, PhD).
Green, fresh from a position in the molecular diagnostic testing industry, joined the Duke Pathology (with salary support from DCI) in the spring of 2019 as senior research program leader of the Molecular Tumor Board and main user and manager of Frameshift MRT. She tracks promising clinical trials and new FDA drug approvals and has configured Frameshift MRT to automatically send therapy alerts to providers when their patients' molecular profiles match any known anti-cancer drug(s). This match could include drugs that are already FDA-approved, drugs that are “emerging” with strong clinical evidence, drugs that are being tested in clinical trials, or drugs that are approved or being trialed in another cancer type.
Over the course of the COVID-19 pandemic, Green has made several significant changes to Frameshift MRT that make it more user-friendly, interactive, and accessible for clinicians and researchers, who can access the Frameshift MRT dashboard when logged into the Duke VPN. Green is available to train and advise.
Part of a Special Report by Duke Cancer Institute the Department of Pathology, Duke University School of Medicine — as featured in the 2021-22 Department of Pathology Annual Report
The Duke BioRepository & Precision Pathology Center (BRPC, a clinical research and discovery Shared Resource with its administrative home in the Department of Pathology, was launched in 2012 with a five-year three-million-dollar investment from Duke Cancer Institute and the Duke University School of Medicine. Spurred by key investments in technology, services, and personnel, the BRPC grew, thrived, and progressively built a national reputation.
“It’s success,” notes BRPC director and DCI pathologist Shannon McCall, MD, “represents the evolution and extension of the Department of Pathology’s support and commitment to cancer research."
The BRPC has served as the biospecimen/pathology core for several U.S. government-funded, multi-institutional, and homegrown studies at Duke Cancer Institute (DCI).
The inclusion of at least one core, McCall notes, and often more than one core, is required for large program-level government grants.
“A strong BRPC, plus a strong Biostatistics Core (another DCI/School of Medicine Shared Resource) and/or the Bioinformatics Core boosts the competitiveness of DCI for these big grants,” notes McCall.
McCall herself is American Board of Pathology-certified in Clinical Informatics as well as Anatomic/Clinical Pathology and General Pathology and is chair of the Biorepository Accreditation Program Committee of the College of American Pathologists. She has been involved in numerous translational cancer research projects that rely on the study of human biological samples and data-driven research. With a research focus on upper GI tract carcinogenesis, she previously served as a member of the data analysis working group for The Cancer Genome Atlas (TCGA) esophageal and pan-GI projects.
Under McCall's leadership,DCI joined a national molecular registry of tumors — the American Association for Cancer Research's PROJECT GENIE (Genomics Evidence Neoplasia Information Exchange) — and became the base for the National Cancer Institute-supported Southern Division of the Cooperative Human Tissue Network.
Leading cancer pathologists with the BRPC, like McCall, have worked and continue to work hand in glove with other DCI investigators on several major cancer research grants, which are described below.
On Oct. 6, Susan Dent, MD, was presented with theInternational Cardio-Oncology Society (IC-OS) Thomas L. Force Pioneer Award in recognition of her achievements in the field.
Aprofessor of medicine, cardio-oncologist, breast oncologist, associate director of Clinical Research, Duke Cancer InstituteBreast Cancer Disease Group,and clinical director of theDuke Consortium for Inflammatory Breast Cancer, Dentaccepted the award upon delivering the Thomas Force Leadership in Cardio-Oncology Lectureatthe2022 Global Cardio-Oncology Summit held in Toronto. The meeting was hosted by theCanadian Cardiac Oncology Network—a not-for-profit organization devoted to the optimization of cancer care for patients without compromising cardiovascular health — thatDent founded in 2011.
"I really want to thank you personally for all that you've done over the years. And I am so proud that you will accept this award and will be recognized as a pioneer in the International Cardio-Oncology Society," said Daniel Lenihan, MD, founder and past president of IC-OS, ina videoproduced to recognize Dent with the award.
Last month, three Duke Cancer Institute facultyin the Department of OB-GYN, Division of Gynecologic Oncology —Brittany Davidson, MD;Haley Moss, MD, MBA; andAngeles Alvarez Secord, MD, MSc—andaDCI faculty member in the Department of Medicine, Division ofPopulation Health Sciences (Arif Kamal, MD, MBA, MHS)participated in national-level events under the auspices of theWhite House Cancer Moonshot Initiative.
First launched in 2016 by the Obama administration and led by then-Vice President Joe Biden to“accelerate scientific discovery in cancer, foster greater collaboration, and improve the sharing of cancer data,” theCancer Moonshotwas reignited in February 2022 byPresident Joe Biden and First Lady Jill Biden,Ed.D.The new goals are to “reduce the cancer death rate by half within 25 years and to improve the lives of people with cancer and cancer survivors.”(The Cancer Moonshot was not active during the Trump administration.)
In October, the focus was on breast and gynecologic cancers.
UPDATE: Shelley Hwang, MD, MPH, is now director of the Breast Cancer Disease Group at Duke Cancer Institute.
An earlier version (below) published on August 19, 2021, reflected her appointment as interim director.
Shelley Hwang, MD, MPH, has been named interim director of the Breast Cancer Disease Group at Duke Cancer Institute.
Executive director of DCI Michael B. Kastan, MD, PhD; DCI chief medical officer Edwin P. Alyea, MD; and DCI chief administrator Robin Famiglietti, PhD, MBA, FACHE, made the announcement on July 30.
"Dr. Hwang is recognized nationally for her leadership in clinical care, research and education, and she has been influential here at Duke in building our cancer program," said Kastan. "We want to express our gratitude to Dr. Hwang for leading us in this important work."
Currently vice chair of Research in the Department of Surgery, The Mary and Deryl Hart Distinguished Professor of Surgery, and a professor in the Department of Radiology, Hwang joined Duke a decade ago after an impressive career at the University of California, San Francisco.
In 2016,Timemagazine named Hwang one of the 100 most influential people for her work in re-framing the problem of pre-invasive breast cancer. Her work continues on this front and she remains a national leader in this area of breast cancer research and treatment.
Hwang, with Rob West, MD, PhD (Stanford University) and Carlo Maley, PhD, MSc (Arizona State University), is a co-principal investigator for theBreast Pre-Cancer Atlasinitiative — part of theNCI Human Tumor Atlas Network.The Breast Pre-Cancer Atlas is being developed to better understand ductal carcinoma in situ (DCIS), a pre-invasive breast cancer precursor.
As interim director of the Breast Cancer Disease Group, Hwang will help advance DCI's vision of programmatic excellence in clinical care, innovative clinical research, translational research and basic science discovery.
"Dr. Hwang will support the success of the individual faculty within the program, facilitating appropriate mentoring and career development activities in collaboration with division chiefs and department chairs," said Alyea. "She will partner with the program leaders in the other disease groups to assure a unified, aligned and highly productive oncology program."
Breast medical oncologist P. Kelly Marcom, MD, held the role of director of the Breast Cancer Disease Group until his retirement from clinical practice this May. Susan Dent, MD, associate director, Clinical Research, and Donald McDonnell, PhD, associate director, Basic Science Research, for the Breast Cancer Disease group both remain in these roles.
Studies in mice suggest the therapy could be a new approach to fighting lethal disease
In animal studies led by researchers atDuke Cancer Institute, a drug approved to treat leukemia successfully disrupted the ability of HER2-positive breast cancer tumors from colonizing the brain.
The finding, appearing online Aug. 30 in the journal Cell Reports, provides evidence for human trials and suggests a potential new approach to derail one of the main ways that breast cancer turns deadly.
“We have made huge strides in treating HER2-positive breast cancers, but when tumors escape the therapies, they often metastasize to the brain,” said senior authorAnn Marie Pendergast, PhD, professor and vice chair of theDepartment of Pharmacology and Cancer Biologyat Duke University School of Medicine.
“When brain metastasis occurs, treatments are unsuccessful either because the tumors have developed resistance, or the therapies cannot penetrate the blood-brain barrier,” Pendergast said. “This remains a devastating diagnosis for patients.”
Pendergast and colleagues looked at how HER2 promotes breast cancer growth, particularly after becoming resistant to targeted treatments that have been highly successful in prolonging lives. The HER2 protein is a driving force in 30% of breast cancers, with approximately 45% of these leading to brain metastases.
The researchers focused on a pair of enzymes called ABL1 and ABL2 kinases that regulate the expression of HER2. The researchers found that these kinases play a critical role in creating the conditions that allow HER2 to accumulate on the surface of breast cancer cells, fueling breast cancer tumor metastasis.
Experimenting in mice, Pendergast and her team were able to disrupt the ABL kinases using a leukemia drug called asciminib. A kinase inhibitor, the drug is not impeded by the blood-brain barrier in tumor-bearing mice and interferes with the ABL kinases’ signaling mechanism.
By blocking the ABL signaling network, the therapy keeps the HER2 protein from accumulating in the breast cancer cells and shuts down their process for fueling the proliferation and spread of cancer cells.
“These findings support the use of ABL kinase inhibitors for the treatment of HER2-positive brain metastasis,” Pendergast said.
In addition to Pendergast, study authors include Courtney M. McKernan, Aaditya Khatri, Molly Hannigan, Jessica Child, Qiang Chen, Benjamin Mayro, David Snyder, and Christopher V. Nicchitta.
The study received funding support from the Department of Defense (W81XWH-18-1-0403, W81XWH-22-10033), the National Institutes of Health (F31CA224952, F31CA243293, F99CA264162, 1R38HL143612, Q10GM101533, Q10GM118630), the National Cancer Institute (P30CA014236), and the Duke Cancer Institute and Translating Duke Health Initiative.
The NIH Heart, Lung and Blood Institute (NHLBI), has awarded a $3M grant to Atrium Health Wake Forest Baptist Comprehensive Cancer Center, VCU Massey Cancer Center, and Duke Cancer Institute to collaborate in a first-of-its-kind prospective study about the long-term heart health of young breast cancer survivors.
The cross-institutional study will help researchers uncover the earliest signs of heart vessel damage in pre-menopausal breast cancer survivors and aims to prevent heart disease in this patient population.
Professor of Medicine Susan Dent, MD — a cardio-oncologist, breast oncologist, and associate director, Clinical Research, for the Duke Cancer Institute Breast Cancer Disease Group — is lead investigator for patients enrolling at DCI.
Learn More About This Study
The American Association for Cancer Research (AACR) held a Virtual Congressional Briefing on June 8 to release the AACR Cancer Disparities Progress Report 2022.
The goal of this report is "to increase public awareness and understanding of cancer health disparities, highlight areas of recent progress in reducing cancer health disparities and provide specific recommendations for achieving health equity."
The report was developed by preeminent cancer disparities researchers, including deputy director of Duke Cancer Institute Steven Patierno, PhD. The briefing on June 8 featured Congresswoman Brenda Lawrence (D-MI) and Senator Shelley Moore Capito (R-WV) and included testimonies and a LIVE panel discussion with leading cancer disparities researchers, including Patierno, as well as survivors of cancer whose stories are included in the report.
Learn more and download report